DK3289080T3 - Genterapi til autosomalt dominante sygdomme - Google Patents
Genterapi til autosomalt dominante sygdomme Download PDFInfo
- Publication number
- DK3289080T3 DK3289080T3 DK16787314.0T DK16787314T DK3289080T3 DK 3289080 T3 DK3289080 T3 DK 3289080T3 DK 16787314 T DK16787314 T DK 16787314T DK 3289080 T3 DK3289080 T3 DK 3289080T3
- Authority
- DK
- Denmark
- Prior art keywords
- autosomal dominant
- dominant diseases
- generation therapy
- therapy
- generation
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154966P | 2015-04-30 | 2015-04-30 | |
| PCT/US2016/030475 WO2016176690A2 (en) | 2015-04-30 | 2016-05-02 | Gene therapy for autosomal dominant diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3289080T3 true DK3289080T3 (da) | 2021-11-08 |
Family
ID=57198841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16787314.0T DK3289080T3 (da) | 2015-04-30 | 2016-05-02 | Genterapi til autosomalt dominante sygdomme |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190275168A1 (da) |
| EP (2) | EP4008780A1 (da) |
| DK (1) | DK3289080T3 (da) |
| ES (1) | ES2898917T3 (da) |
| PT (1) | PT3289080T (da) |
| WO (1) | WO2016176690A2 (da) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US20150166985A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting von willebrand factor point mutations |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| ES3013183T3 (en) | 2014-11-21 | 2025-04-11 | Regeneron Pharma | Methods for targeted genetic modification using paired guide rnas |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| CA3014671A1 (en) | 2016-03-01 | 2017-09-08 | University Of Florida Research Foundation, Inc. | Aav vectors for treatment of dominant retinitis pigmentosa |
| RU2745563C2 (ru) | 2016-05-20 | 2021-03-29 | Регенерон Фармасьютикалс, Инк. | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк |
| MX2019000262A (es) * | 2016-07-05 | 2019-05-27 | Univ Johns Hopkins | Composiciones basadas en crispr/cas9 y metodos para el tratamiento de degeneraciones retinianas. |
| EP3494215A1 (en) | 2016-08-03 | 2019-06-12 | President and Fellows of Harvard College | Adenosine nucleobase editors and uses thereof |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| IT201600102542A1 (it) * | 2016-10-12 | 2018-04-12 | Univ Degli Studi Di Trento | Plasmide e sistema lentivirale contenente un circuito autolimitante della Cas9 che ne incrementa la sicurezza. |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| CN110139654A (zh) * | 2016-11-03 | 2019-08-16 | 优美佳生物技术有限公司 | 用于细胞重编程的方法和组合物 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| CA3053499A1 (en) | 2017-02-15 | 2018-08-23 | Bluebird Bio, Inc. | Donor repair templates multiplex genome editing |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110662556A (zh) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | 癌症疫苗 |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| IL269458B2 (en) | 2017-03-23 | 2024-02-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US20200172927A1 (en) * | 2017-05-15 | 2020-06-04 | The Trustees Of Columbia University In The City Of New York | Reprogramming metabolism by inhibiting vhl for treatment of neurodegeneration |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3661523A4 (en) * | 2017-08-03 | 2021-08-04 | University of Iowa Research Foundation | TREATMENT METHODS FOR GENETIC HEARING LOSS |
| US11806408B2 (en) * | 2017-08-28 | 2023-11-07 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating cone-rod retinal dystrophy |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| EP3690045A2 (en) * | 2017-09-29 | 2020-08-05 | Toolgen Incorporated | Gene manipulation for treatment of retinal dysfunction disorder |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| JP2021502978A (ja) * | 2017-11-15 | 2021-02-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 網膜ジストロフィーを治療するｒｄｈ１２コード領域を含むウイルスベクターおよび方法 |
| MA50877A (fr) * | 2017-11-21 | 2020-09-30 | Bayer Healthcare Llc | Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN108034709B (zh) * | 2017-12-18 | 2021-05-07 | 青岛大学 | Guca1a基因在制备检测视锥细胞营养不良制品中的应用 |
| EP3768327A4 (en) * | 2018-03-23 | 2022-04-13 | The Trustees of Columbia University in the City of New York | GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES |
| EP3784292A4 (en) * | 2018-04-27 | 2022-01-19 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | THERAPEUTIC GENOME EDITING IN HYPER-IGM SEX-LINKED SYNDROME |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019232517A1 (en) | 2018-06-01 | 2019-12-05 | University Of Florida Research Foundation, Incorporated | Compositions and methods for treatment of dominant retinitis pigmentosa |
| US12275957B2 (en) | 2018-06-09 | 2025-04-15 | Arizona Board Of Regents On Behalf Of Arizona State University | Next generation designer liver organoids and their methods of preparation and use |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| EP3829652A4 (en) * | 2018-08-01 | 2022-05-11 | University of Maryland, Baltimore | MODULATION OF MTORC1 ACTIVITY AND AUTOPHAGY BY CIB2-RHEB INTERACTION |
| CN110857440B (zh) * | 2018-08-23 | 2021-02-19 | 武汉纽福斯生物科技有限公司 | 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用 |
| CA3116452A1 (en) * | 2018-10-15 | 2020-04-23 | Fondazione Telethon | Genome editing methods and constructs |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN109456995A (zh) * | 2018-11-08 | 2019-03-12 | 杜以军 | 基因敲除质粒、细胞系及制备方法和应用 |
| WO2020140007A1 (en) * | 2018-12-28 | 2020-07-02 | University Of Rochester | Gene therapy for best1 dominant mutations |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN113631710A (zh) * | 2019-02-25 | 2021-11-09 | 爱迪塔斯医药公司 | 用于治疗rho相关的常染色体显性视网膜色素变性(adrp)的crispr/rna指导的核酸酶相关方法和组合物 |
| AU2020242032A1 (en) | 2019-03-19 | 2021-10-07 | Massachusetts Institute Of Technology | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114450031A (zh) * | 2019-07-10 | 2022-05-06 | 洛卡纳生物股份有限公司 | 靶向rna的敲低和替代组合物及使用方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| MX2022005572A (es) | 2019-11-08 | 2022-06-09 | Regeneron Pharma | Estrategias crispr y aav para la terapia de retinosquisis juvenil ligada al cromosoma x. |
| CN110923333B (zh) * | 2019-12-11 | 2020-09-29 | 湖北省农业科学院畜牧兽医研究所 | 山羊zbp1基因第一内含子内与产羔数关联的单倍型标记及其应用 |
| AU2021226603A1 (en) * | 2020-02-28 | 2022-10-27 | The Trustees Of The University Of Pennsylvania | Treating autosomal recessive bestrophinopathies and methods for evaluating same |
| CN111484981B (zh) * | 2020-04-26 | 2021-02-02 | 四川省人民医院 | 一种用于构建视网膜新生血管疾病模型的方法和应用 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| CA3207527A1 (en) | 2021-02-05 | 2022-08-11 | Eric B. Kmiec | Methods of and compositions for reducing gene expression and/or activity |
| US20240207448A1 (en) * | 2021-04-16 | 2024-06-27 | Editas Medicine, Inc. | Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp) |
| KR20250123260A (ko) * | 2024-02-07 | 2025-08-18 | 건국대학교 글로컬산학협력단 | Nr2f1 억제제를 포함하는 안과 질환의 예방 또는 치료용 약학 조성물 |
| CN118421630B (zh) * | 2024-05-20 | 2025-03-11 | 中国医学科学院北京协和医院 | 一种靶向RP1L1基因的sgRNA导向序列及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| EP0682699B1 (en) | 1993-02-12 | 2003-05-07 | The Johns-Hopkins University | FUNCTIONAL DOMAINS IN $i(FLAVOBACTERIUM OKEANOKOITES) (FOKI) RESTRICTION ENDONUCLEASE |
| US8551970B2 (en) * | 1996-04-02 | 2013-10-08 | Optigen Patents Limited | Genetic suppression and replacement |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| DK2816112T3 (da) | 2009-12-10 | 2018-11-19 | Univ Minnesota | TAL-effektor-medieret DNA-modifikation |
| GB201004475D0 (en) * | 2010-03-17 | 2010-05-05 | Isis Innovation | Gene silencing |
| EP3825406A1 (en) * | 2013-06-17 | 2021-05-26 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
| SG10201913026TA (en) * | 2013-07-09 | 2020-02-27 | Harvard College | Multiplex rna-guided genome engineering |
-
2016
- 2016-05-02 EP EP21186523.3A patent/EP4008780A1/en active Pending
- 2016-05-02 EP EP16787314.0A patent/EP3289080B1/en active Active
- 2016-05-02 ES ES16787314T patent/ES2898917T3/es active Active
- 2016-05-02 WO PCT/US2016/030475 patent/WO2016176690A2/en not_active Ceased
- 2016-05-02 DK DK16787314.0T patent/DK3289080T3/da active
- 2016-05-02 PT PT167873140T patent/PT3289080T/pt unknown
- 2016-05-02 US US15/569,920 patent/US20190275168A1/en not_active Abandoned
-
2024
- 2024-08-05 US US18/794,752 patent/US20250235556A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3289080A2 (en) | 2018-03-07 |
| EP3289080A4 (en) | 2018-10-03 |
| US20250235556A1 (en) | 2025-07-24 |
| PT3289080T (pt) | 2021-11-19 |
| EP3289080B1 (en) | 2021-08-25 |
| WO2016176690A2 (en) | 2016-11-03 |
| US20190275168A1 (en) | 2019-09-12 |
| WO2016176690A3 (en) | 2016-12-01 |
| EP4008780A1 (en) | 2022-06-08 |
| ES2898917T3 (es) | 2022-03-09 |
| HK1251615A1 (zh) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3289080T3 (da) | Genterapi til autosomalt dominante sygdomme | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| HUE059662T2 (hu) | Eljárás terápiás immunsejtek hatékonyságának fokozására | |
| EP3314027A4 (en) | THERAPEUTIC OLIGONUCLEOTIDES | |
| DK3211071T3 (da) | Fremstillingsfremgangsmåde til retinalt væv | |
| DK3328880T3 (da) | Terapeutiske midler | |
| DK3356313T3 (da) | 2-perfluorhexyloktan til oftalmisk indgivelse | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| DK3370760T3 (da) | Plasminogenerstatningsterapi til plasminogenmangel | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| LT3169328T (lt) | Chinolino dariniai, skirti uždegiminių ligų gydymui | |
| DK3262066T4 (da) | Genterapi | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| DK3612624T3 (da) | Genterapi | |
| EP3317241A4 (en) | THERAPEUTIC INHIBITING COMPOUNDS | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| DK3310432T3 (da) | Indretning til effektiv ikke-invasiv to-trinsneurostimulation | |
| DK3294769T3 (da) | Behandling for multipelt myelom (mm) | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| IL262851A (en) | Combination prime: boost therapy |